IVD, RUO or Chemical: Classifying Laboratory Kits

Two laboratory kits standing on the same shelf can belong to two different universes in the regulatory world: one, as an in vitro diagnostic product, is the subject of the medical device legislation; the other, with its research-use-only statement, passes through the general chemical product regime. What decides the difference is neither the chemical composition nor the size of the box; the deciding factor is the manufacturer's declared intended use. If the kit is designed to produce diagnostic results, it is an IVD; if it is declared for research use only, it is assessed outside the medical device scope; general-purpose chemicals not entering the diagnosis of human or animal disease fall under chemical legislation. This triple distinction determines which document set the importer takes to customs, which inspection route the shipment catches, and under which surveillance the product lives after placing on the market. This article explains how the three statuses are distinguished, how the claim analysis is done and how the import file is built.

Who is this for?

This guide is for every institution with laboratory consumption and every supply chain role. Distributors and suppliers must separate the products in their portfolio by status, because a single order basket can contain products from all three statuses side by side. Procurement teams prevent bringing products in the wrong status by clarifying the intended use at the order stage. Laboratory managers must be aware that an RUO product will not be used in clinical diagnosis and must protect that boundary with internal processes. Quality units track the status distinction label by label in acceptance and stock management. Regulatory teams prepare opinion files for borderline products. Customs brokers tie the status-appropriate document set to the declaration. Clinical research teams reflect the status of the kits to be used in the investigation into the protocol. At audit the question is a single sentence: in which status, with which document, does this box stand here.

Which products does it cover?

The scope approaches the entirety of kits, reagents and preparations used in the laboratory. Diagnostic kits: reagent sets producing clinical diagnostic information from human samples, together with calibrators and control materials. RUO products: kits, antibodies, dyes and protocol components declared for research use only. General chemicals: solvents, salts, buffers, standard laboratory chemicals and preparation materials. Those standing at the border: platforms usable in both clinical and research environments, kits carrying an RUO label but with content close to diagnostic purpose, veterinary products, food and environmental tests. Animal or food-purpose kits can be tied to different regimes since they remain outside human diagnosis. Products containing medicinal or biological material must be assessed separately. On the GTİP side, diagnostic reagents and kits separate in the tariff schedule; chemical preparations distribute to other positions. If a product set contains components in more than one status, the distinction must be made component by component and the file built accordingly.

When does it apply?

Status assessment is applied before new product procurement and when the product portfolio changes. The critical moments are these. If the supplier's product label carries an RUO statement but the purchase request arises from a clinical diagnostic need, there is a status contradiction and the purchase should be stopped. If the manufacturer launches the kit for diagnostic purposes in a new market, the status changes and conformity assessment comes onto the agenda. An RUO kit within a research project cannot produce clinical decisions; use outside the protocol frame creates a product safety problem. Institutions using the same kit in different laboratory types must embed the research laboratory versus clinical laboratory distinction into their processes. If the product's advertising and marketing language slides toward a diagnostic claim, the status silently changes; a status check should be added to the marketing approval flow. At import inspection the label claim is compared with the document set; bringing an RUO-labelled product with diagnostic documents produces a contradiction. On shared platforms, which kit runs in which status must be recorded.

Legal framework and authority

The three statuses have three separate legal grounds. IVD status comes from the medical device legislation: Türkiye applies the European regulation on in vitro diagnostic devices nationally; scope, classification, conformity assessment and placing-on-market rules are set in that frame, and the competent authority is TİTCK. RUO status means the device legislation does not apply to products outside the medical device definition; but the product then meets chemical and product safety legislation and the general product regime. Chemical status brings the obligations of classification, labelling and safety data sheets for chemicals; the relevant ministries are competent in their own fields. On the import side all statuses meet the foreign-trade controls: the product safety communiqués and the Import Regime Decision determine the inspection mechanism by GTİP. This multi-layeredness means a single product's file can carry traces of three legislations. Current regulation texts, communiqué annexes and guides must be tracked from official sources, and the status decision must be filed with written rationale.

Step-by-step process

1. Collect the product's declared intended use: label, instructions for use, technical sheet and the manufacturer's catalogue text.
2. Run the claim analysis: is the product designed to produce diagnostic information from human samples; extract the claim sentences one by one.
3. Give the status decision and justify it: IVD, RUO or chemical; file it with a decision form and claim table.
4. In IVD status, determine the conformity assessment requirement: class, CE-IVD evidence and registration obligations.
5. In RUO status, document the use boundary: research purpose declaration, recipient laboratory information and the undertaking of non-use in diagnosis.
6. In chemical status, check the safety data sheet and labelling compliance.
7. Make the GTİP classification with rationale; keep the status decision and the tariff decision in separate files.
8. Build the import document set according to status and align it with the customs broker.
9. Add a status flag to acceptance and stock processes; keep the status-based distinction in the depot and the system.
10. Re-check label, claim and portfolio compliance at the annual review.

Document checklist

• Product label and instructions for use, in the original language and in translation.
• Manufacturer's intended use declaration and catalogue text.
• Claim analysis table: diagnostic versus research, sentence by sentence.
• Status decision form: decision, rationale, date, signature.
• If IVD: CE-IVD declaration of conformity, certificate and registration information.
• If RUO: research purpose document and use-boundary undertaking.
• If chemical: safety data sheet and classification information.
• GTİP classification note, rationale and alternative elimination records.
• Supplier correspondence and technical clarification requests.
• Import document set: invoice, declaration, inspection outcomes.

Parties and responsibilities

The chain's fragile link is laboratory use: using an RUO kit in clinical diagnosis collapses the entire status architecture in one move and puts the institution at patient safety risk. Control on the use side is as important as control on the import side.

Exceptions and edge cases

Borderline cases are the heart of this topic. An RUO-labelled kit can be identical in content to its diagnostic counterpart; the difference lies only in the declaration, and the administration looks at actual use: if an RUO product is found in routine clinical diagnosis, it counts as a status violation. Veterinary diagnostic kits are assessed separately, outside human diagnosis. Food, environmental and water tests pass through their own regimes since they do not enter the medical device definition. When clinical diagnostic need arises within research projects, a protocol update and the transition to IVD status should be assessed. The sharpest boundary is this: if research results are tied to treatment decisions, the product is being used de facto for diagnosis. Kits containing active pharmaceutical ingredients or biological material can relate to medicinal legislation. Certificates from non-harmonised third countries do not replace national conformity assessment. Platforms producing informational data slide into IVD status the moment their results enter clinical decisions. In every borderline case the tool is the same: a written claim analysis and a reasoned status decision.

Common mistakes

The most common mistake is treating the RUO label as a status solution; the label alone does not cover actual use. The second is grouping an entire kit family under a single status; diagnostic and RUO variants within a family must be assessed individually. The third is sliding into diagnostic claims in marketing texts; sales language changes the status. The fourth is deriving the GTİP decision from the status decision; the tariff comes from composition. The fifth is carrying IVD evidence over to an RUO product; the document set is inconsistent with the status. The sixth is dropping the safety data sheets of chemical products from the file; the chemical regime demands its own obligations. The seventh is not informing the laboratory of the status difference; a use error also weakens the importer's status decision.

Important notice

This article is general information, not legal or customs advice; for the status of a specific product, the applicable legislation, the manufacturer's declarations and where necessary the competent authority's opinion must govern. GTİP codes and product examples in the text are for orientation; the GTİP examples are not binding and classification must be reasoned separately for every product. Legislation can change; official sources must be checked before any transaction.